CU20120080A7 - Formulaciones de anticuerpo - Google Patents
Formulaciones de anticuerpoInfo
- Publication number
- CU20120080A7 CU20120080A7 CU2012000080A CU20120080A CU20120080A7 CU 20120080 A7 CU20120080 A7 CU 20120080A7 CU 2012000080 A CU2012000080 A CU 2012000080A CU 20120080 A CU20120080 A CU 20120080A CU 20120080 A7 CU20120080 A7 CU 20120080A7
- Authority
- CU
- Cuba
- Prior art keywords
- antibody formulations
- formulations
- cryoprotectants
- cryoprotectant
- buffer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2859CH2009 | 2009-11-20 | ||
| PCT/IB2010/055296 WO2011061712A1 (en) | 2009-11-20 | 2010-11-19 | Formulations of antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20120080A7 true CU20120080A7 (es) | 2012-10-15 |
Family
ID=44059267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2012000080A CU20120080A7 (es) | 2009-11-20 | 2012-05-21 | Formulaciones de anticuerpo |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20120231009A1 (https=) |
| EP (2) | EP2501408B1 (https=) |
| JP (2) | JP5896471B2 (https=) |
| KR (1) | KR101333276B1 (https=) |
| CN (1) | CN102770157B (https=) |
| AU (1) | AU2010320515B2 (https=) |
| BR (1) | BR112012012080B1 (https=) |
| CA (1) | CA2781467C (https=) |
| CU (1) | CU20120080A7 (https=) |
| DK (1) | DK3721904T3 (https=) |
| ES (1) | ES2897500T3 (https=) |
| IL (1) | IL219884A (https=) |
| MX (1) | MX2012005863A (https=) |
| MY (1) | MY165614A (https=) |
| NZ (1) | NZ600096A (https=) |
| PL (1) | PL3721904T3 (https=) |
| PT (1) | PT3721904T (https=) |
| RU (1) | RU2548772C2 (https=) |
| WO (1) | WO2011061712A1 (https=) |
| ZA (1) | ZA201204459B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| WO2009113083A1 (en) | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| SG192117A1 (en) | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| KR102063028B1 (ko) | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| PE20150964A1 (es) | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| CN104780940B (zh) | 2012-11-06 | 2017-11-07 | 拜耳制药股份公司 | 用于双特异性t细胞衔接体(bites)的制剂 |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| EP3024485B1 (en) | 2013-07-23 | 2020-11-18 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| WO2015181757A1 (en) * | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CN104922668B (zh) * | 2014-12-10 | 2019-08-23 | 信达生物制药(苏州)有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| KR102546471B1 (ko) * | 2016-09-27 | 2023-06-21 | 프레제니우스 카비 도이치란트 게엠베하 | 액상의 약학 조성물 |
| ES2991182T3 (es) | 2016-10-21 | 2024-12-02 | Biocon Ltd | Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus |
| CN106800598B (zh) * | 2017-02-09 | 2020-08-07 | 广州桂雨生物科技有限公司 | 一种抗体保存液及其制备方法 |
| WO2019180261A1 (en) * | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| US11498626B2 (en) | 2020-11-11 | 2022-11-15 | Rivian Ip Holdings, Llc | Vehicle tailgate assembly |
| CN113289027B (zh) * | 2021-05-18 | 2022-07-01 | 中国兽医药品监察所 | 一种通用型单克隆抗体耐热保护剂 |
| WO2024083074A1 (en) * | 2022-10-17 | 2024-04-25 | Beigene, Ltd. | Formulations containing anti-tigit antibody and methods of use thereof |
| CN117214426A (zh) * | 2023-09-20 | 2023-12-12 | 暨南大学 | 一种用于免疫组织化学检测的抗体稀释液及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2434840T3 (es) * | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5810597A (en) * | 1996-06-21 | 1998-09-22 | Robert H. Allen, Jr. | Touch activated audio sign |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| WO2007142667A2 (en) * | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
| CA2654794A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| CL2007003583A1 (es) * | 2006-12-11 | 2008-07-18 | Hoffmann La Roche | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
| CN101199483B (zh) * | 2006-12-14 | 2011-01-26 | 上海中信国健药业股份有限公司 | 一种稳定的抗her2人源化抗体制剂 |
| KR101482959B1 (ko) * | 2006-12-26 | 2015-01-15 | 센트로 데 인뮤놀러지아 모레큘러 | Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물 |
| CA2674608A1 (en) * | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| WO2009037190A2 (en) * | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
| AU2021400284A1 (en) * | 2020-12-15 | 2023-06-22 | Bicara Therapeutics Inc. | Pharmaceutical formulations for fusion proteins |
-
2010
- 2010-11-19 EP EP10831248.9A patent/EP2501408B1/en active Active
- 2010-11-19 NZ NZ600096A patent/NZ600096A/xx unknown
- 2010-11-19 MY MYPI2012002248A patent/MY165614A/en unknown
- 2010-11-19 CA CA2781467A patent/CA2781467C/en active Active
- 2010-11-19 PT PT201747839T patent/PT3721904T/pt unknown
- 2010-11-19 DK DK20174783.9T patent/DK3721904T3/da active
- 2010-11-19 AU AU2010320515A patent/AU2010320515B2/en active Active
- 2010-11-19 RU RU2012125254/15A patent/RU2548772C2/ru active
- 2010-11-19 KR KR1020127015910A patent/KR101333276B1/ko active Active
- 2010-11-19 MX MX2012005863A patent/MX2012005863A/es active IP Right Grant
- 2010-11-19 BR BR112012012080-8A patent/BR112012012080B1/pt active IP Right Grant
- 2010-11-19 PL PL20174783T patent/PL3721904T3/pl unknown
- 2010-11-19 EP EP20174783.9A patent/EP3721904B1/en active Active
- 2010-11-19 WO PCT/IB2010/055296 patent/WO2011061712A1/en not_active Ceased
- 2010-11-19 JP JP2012539465A patent/JP5896471B2/ja active Active
- 2010-11-19 US US13/510,929 patent/US20120231009A1/en not_active Abandoned
- 2010-11-19 ES ES20174783T patent/ES2897500T3/es active Active
- 2010-11-19 CN CN201080060508.0A patent/CN102770157B/zh active Active
-
2012
- 2012-05-20 IL IL219884A patent/IL219884A/en active IP Right Grant
- 2012-05-21 CU CU2012000080A patent/CU20120080A7/es unknown
- 2012-06-18 ZA ZA2012/04459A patent/ZA201204459B/en unknown
-
2015
- 2015-12-28 JP JP2015256586A patent/JP2016104780A/ja active Pending
-
2018
- 2018-11-20 US US16/197,228 patent/US20190321285A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/085,316 patent/US20210290525A1/en not_active Abandoned
-
2023
- 2023-05-19 US US18/199,675 patent/US20240058263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20120080A7 (es) | Formulaciones de anticuerpo | |
| CY1123909T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| CR11005A (es) | Formulaciones estables de anticuerpos | |
| AR079556A1 (es) | Formacion de anticuerpos | |
| CO6751287A2 (es) | Composición antigénetica de micobacteria | |
| PH12014501628A1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| PE20141175A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| WO2008008364A3 (en) | Enhanced stability phenylephrine liquid compositions | |
| DOP2009000157A (es) | Agentes para combatir parasitos en animales | |
| BRPI0915076A2 (pt) | composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas. | |
| DK1802344T3 (da) | Antistofformulering i histidin-acetat-puffer. | |
| MX2008011085A (es) | Composiciones antimicrobianas y metodos para sellar cateteres. | |
| WO2011103490A3 (en) | INTEGRIN αVβ8 NEUTRALIZING ANTIBODY | |
| AR061348A1 (es) | Preparados estables de laquinimod | |
| CL2012002695A1 (es) | Articulo para fumar, que comprende una primera parte que contiene una fuente de material para fumar y una segunda parte que tiene al menos un extremo que esta configurado para desplazarse en relacion con la primera parte, en donde el articulo ademas comprende un agente modificador de humo que se libera en el articulo para fumar; y envase. | |
| CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
| AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
| CL2013000098A1 (es) | Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. | |
| NI201000189A (es) | Formulación de medicamento sólido con liberación retardadas. | |
| WO2011028961A3 (en) | Anti-botulism antibody coformulations | |
| BR112013013117A2 (pt) | agente hidrotrópico, uso do mesmo para tornar solúveis tensoativos não iônicos e composições contendo os mesmos | |
| BR112014003139A2 (pt) | musgo de turfa umectável resistente à lixiviação, método de preparação, e método de uso | |
| ECSP13013093A (es) | Composiciones líquidas de limpieza de sal | |
| CL2015001565A1 (es) | Composición, en forma de suspensión acuosa, que comprende al menos un compuesto de triazina, un principio activo adicional y uno o más tensioactivos; kit que comprende la composición; método de preparación y uso de un tesioactivo. | |
| WO2010053610A3 (en) | Stable anthrax vaccine formulations |